Aurobindo Pharma will acquire an additional 20% stake in inhalation products manufacturing joint venture Luoxin Aurovitas in China from the JV partner for $5.125 million.
Besides the 20% stake that is expected to be acquired within next three months, it will have the right to acquire balance 50% stake by December 2029 at an agreed price of $18.86 mn subject to certain terms and conditions.
The Hyderabad-based drugmaker in a filing on Tuesday said subsidiary Helix Healthcare and Chinese partner Shandong Luoxin in the 30:70 joint venture entered into a binding agreement on December 22 for the stake acquisition. On the objective behind acquiring additional stake, Aurobindo Pharma said it is to expand the manufacturing to economies of scale by adding 2 high speed lines and cater market demand.
Luoxin Aurovitas was set up as a JV for manufacturing inhalation products in China on March 25, 2019. Its current net worth is $15.29 million.
Published – December 23, 2025 11:37 pm IST
